Dr. Qiaoyu Liu earned her PhD in Pharmaceutical Sciences from Shenyang Pharmaceutical University in 2022 under the supervision of Prof. Shirui Mao. She continued her academic training as a postdoctoral researcher in the Ghent Research Group on Nanomedicines at Ghent University, in the group of Prof. Koen Reamdonck. In 2025, she has been appointed to Department of Pharmaceutics at Xinjiang Medical University, China. She has (co-)authored 16 peer-reviewed publications. Among these, her five first-author papers, which are published on journals such as J. Control. Release, Acta Biomater., and Drug Discov. Today, have alone garnered over 300 citations. Her research is centered on pulmonary drug delivery, with a specific focus on overcoming the fundamental challenge of transporting small molecules and nucleic acids across the complex biological barriers of the lung. Within this field, she has developed deep expertise spanning multiple critical areas: the formulation design of dry powder inhalers, the development of novel inhalable mRNA-LNP therapeutics, the investigation into the pivotal role of pulmonary surfactants, and the pioneering advancement of inhalable nanomedicines for targeted lung cancer therapy.